Skip to content
Taxonomy
CMTA Invests $423K to Accelerate CMT Diagnostics and Gene Discovery
CMTA announced today a $423,000 investment to address diagnostic gaps Read More
Encouraging News in CMT Research from CMTA-STAR Alliance Partner Alesta Therapeutics
Alesta Therapeutics, a CMTA-STAR Alliance Partner focused on developing therapies Read More
Nervosave: Shaping the Future of Genetic Therapy for CMT1A
What is the Nervosave Survey? CMTA-STAR Alliance Partner Nervosave Therapeutics, Read More
CMTA-STAR Alliance Partner NMD Pharma Announces FDA Orphan Drug Designation for NMD670
NMD Pharma A/S, a CMTA-STAR Alliance Partner, recently announced that Read More
CMTA-STAR Alliance Partner NMD Pharma Publishes Transformative Study on Charcot-Marie-Tooth Disease
CMTA-STAR Alliance Partner NMD Pharma A/S has announced the publication Read More
CMTA-STAR Collaboration Celebrates a Decade of CMT Genetic Discovery Through the GENESIS Database
Exciting progress from CMTA’s Strategy To Accelerate Research (STAR) program Read More
Alliance Partner NMD Pharma A/S Launches Phase II SYNAPSE-CMT Trial with First Patient Dosed at CMTA Center of Excellence
The Charcot-Marie-Tooth Association (CMTA) congratulates CMTA-STAR Alliance Partner NMD Pharma Read More
CMTA-INC Strategic Alliance Announces the 2025 Inherited Neuropathy Fellowship
The Charcot-Marie-Tooth Association (CMTA), through its strategic alliance with the Read More
Advancements in CMT1A and CMT1B Research Highlight CMTA’s Impact
Exciting news from a CMTA-STAR-funded research project has been published Read More
Gene Therapy for CMT1A, 1B, and X1: Progress in Nanoparticles
In a jointly-funded project between CMTA and the Muscular Dystrophy Read More
